Efficacy and safety of once-monthly Risperidone ISM(®) in schizophrenic patients with an acute exacerbation

To evaluate the efficacy and safety of Risperidone ISM(®) against placebo in patients with acute exacerbation of schizophrenia. A multicenter, randomized, double-blind, placebo-controlled study was conducted between June 2017 and December 2018 (NCT03160521). Eligible patients received once-monthly i...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Christoph U., Litman, Robert E., Filts, Yuriy, Llaudó, Jordi, Naber, Dieter, Torres, Ferran, Martínez, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688968/
https://www.ncbi.nlm.nih.gov/pubmed/33239746
http://dx.doi.org/10.1038/s41537-020-00127-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688968/
https://www.ncbi.nlm.nih.gov/pubmed/33239746
http://dx.doi.org/10.1038/s41537-020-00127-y

Ejemplares similares